ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 5 of 89 for:    Recruiting, Not yet recruiting, Available Studies | "Muscular Dystrophies"

Plus Epicatechin Duchenne Muscular Dystrophy in Non-ambulatory Adolescents

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02964377
Recruitment Status : Recruiting
First Posted : November 16, 2016
Last Update Posted : November 16, 2016
Sponsor:
Collaborator:
Cardero Therapeutics, Inc.
Information provided by (Responsible Party):
Craig McDonald, MD, University of California, Davis

November 7, 2016
November 16, 2016
November 16, 2016
November 2016
April 2017   (Final data collection date for primary outcome measure)
  • Pharmacokinetics Outcome: (+)-epicatechin trough (Cmin) serum concentration [ Time Frame: Baseline, Week 2, Week 4, Week 8 ]
    Pharmacokinetic evaluation for dose-response evaluation.
  • Pharmacokinetics Outcome: (+)-epicatechin peak (Cmax) serum concentration [ Time Frame: Baseline, Week 2, Week 4, Week 8 ]
    Pharmacokinetic evaluation for dose-response evaluation.
  • Laboratory Outcome: Change in plasma follistatin:myostatin ratio [ Time Frame: Baseline, Week 4, Week 8 ]
    Evaluation of follistatin:myostatin ratio from plasma samples.
  • Clinical Outcome: Percent change in cardiac ejection fraction and shortening fraction by MRI [ Time Frame: Baseline, Week 8 ]
    Evaluation of change in cardiac volume and performance.
  • Safety: Clinical laboratory blood chemistry evaluation [ Time Frame: Screening, Baseline, Week 2, Week 4, Week 8 ]
    Evaluation of routine safety laboratory blood chemistry assessments for clinical safety monitoring.
  • Safety: Complete blood count evaluation [ Time Frame: Screening, Baseline, Week 2, Week 4, Week 8 ]
    Evaluation of routine complete blood count for clinical safety monitoring.
  • Safety: Urinalysis [ Time Frame: Screening, Baseline, Week 2, Week 4, Week 8 ]
    Evaluation of routine urinalysis for clinical safety monitoring.
Same as current
No Changes Posted
  • Clinical Outcome: Percent change in normalized upper extremity reachable surface area. [ Time Frame: Baseline, Week 4, Week 8 ]
  • Clinical Outcome: Percent change in Performance of the Upper Limb Assessment score. [ Time Frame: Baseline, Week 4, Week 8 ]
  • Clinical Outcome: Percent change in 6-minute cycle test maximal attained revolutions. [ Time Frame: Baseline, Week 4, Week 8 ]
  • Person-Reported Outcome: Percent change in POSNA Pediatric Outcomes Data Collection Instrument (PODCI) quality of life instrument score [ Time Frame: Baseline, Week 4, Week 8 ]
  • Person-Reported Outcome: Percent change in Person-Reported Outcome Measure Upper Limb (PROM-UL) functional capacity score. [ Time Frame: Baseline, Week 4, Week 8 ]
Same as current
  • Laboratory Outcome: Expression fold change in plasma biomarker panel by SomaSCAN [ Time Frame: Baseline, Week 4, Week 8 ]
    Proteomics evaluation of 1400 circulating biomarkers to identify intervention-responsive biological / pathophysiological pathways.
  • Laboratory Outcome: Expression fold change in plasma biomarker panel by ELISA. [ Time Frame: Baseline, Week 4, Week 8 ]
    Proteomics evaluation of plasma biomarkers to confirm intervention-responsive pathophysiological pathways.
  • Clinical Outcome: Percent change in cardiac circumferential strain by MRI [ Time Frame: Baseline, Week 8 ]
    Cardiac lateral and posterior wall strain by cardiac MRI
Same as current
 
Plus Epicatechin Duchenne Muscular Dystrophy in Non-ambulatory Adolescents
A Single Center Dose Ranging Pilot Study of (+)-Epicatechin in Non-ambulatory Adolescents With Duchenne Muscular Dystrophy and Pre-symptomatic Cardiac Dysfunction
This single center open-label pilot study will enroll 15 non-ambulatory children with Duchenne muscular dystrophy at least 8 years of age and who demonstrate pre-clinical cardiomyopathy (defined as a cardiac ejection fraction >55% with abnormal LV strain by cardiac MRI). They will receive (+)-epicatechin at one of three doses during an 8-week dose-ranging study with assessments at baseline, 2 Weeks, 4weeks, and 8 weeks. The study will determine optimal dosing for future cardiac efficacy studies based on serum / plasma biomarker response using follistatin: myostatin ratio, nitrite/nitrate ratio, cardiac troponins and cardiac BNP. Secondary endpoints will include additional biomarker assessments by SOMAscanTM, cardiac functional evaluations by cardiac MRI (LV strain), and echocardiogram (LV strain by speckle tracking) and measures of strength, range of motion and mobility, and clinical safety assessments. Results of secondary endpoint analysis will be used to refine design of subsequent clinical trials powered to detect changes in clinical outcomes.
Not Provided
Interventional
Phase 1
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Duchenne Muscular Dystrophy
Drug: (+)- Epicatechin
Experimental: Open-label (+)- Epicatechin
8-weeks open-label (+)- Epicatechin at 25mg/day twice per day, 25mg/day three times per day, or 50mg/day at three times per day.
Intervention: Drug: (+)- Epicatechin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
15
Same as current
May 2017
April 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male
  • Age 8 years to 17 years
  • Non-Ambulatory (unable to complete 10m run/walk under 10s)
  • Weight </=100Kg
  • Diagnosis of DMD confirmed by at least one the following:

    • Dystrophin immunofluorescence and/or immunoblot showing complete dystrophin deficiency, and clinical picture consistent with typical DMD, or
    • Gene deletions test positive (missing one or more exons) of the dystrophin gene, where reading frame can be predicted as 'out-of-frame', and clinical picture consistent with typical DMD, or
    • Complete dystrophin gene sequencing showing an alteration (point mutation, duplication, or other mutation resulting in a stop codon mutation) that can be definitely associated with DMD, with a typical clinical picture of DMD, or
    • Positive family history of DMD confirmed by one of the criteria listed above in a sibling or maternal uncle, and clinical picture typical of DMD.
  • Cardiac ejection fraction >55% on echocardiogram
  • Use of nutritional, herbal and antioxidant supplements taken with the intent of maintaining or improving skeletal muscle strength or functional mobility has been discontinued at least 4 weeks prior to screening (daily multivitamin use is acceptable).
  • Glucocorticoid therapy, if used, must have a stable weight-based dose for at least 3 months prior to enrollment
  • Cardiac therapy, if used, includes prophylactic ACE inhibitors, aldosterone receptor antagonists (e.g.

spironolactone, eplerenone, etc.), and/or beta-blocker therapy, and must be stable for 3 months prior to enrollment.

  • Hematology profile within normal range.
  • Baseline laboratory safety chemistry profile within typical range for DMD (elevated ALT / AST acceptable in the absence of elevated GGT, elevated CK acceptable).

Exclusion Criteria:

  • Inability to complete cardiac or strength, range of motion and mobility assessments per protocol
  • Current enrollment in another treatment clinical trial.
  • History of significant concomitant illness or significant impairment of renal or hepatic function.
  • Use of regular daily aspirin or other medication with antiplatelet effects within 3 weeks of first dose of study medication.
  • Cardiac symptoms that, in the opinion of the investigator, may be suggestive of imminent moderate to severe cardiac events, irrespective of LVEF.
Sexes Eligible for Study: Male
8 Years to 17 Years   (Child)
No
Contact: Alina Nicorici, BS 916-734-0968 arnicorici@ucdavis.edu
United States
 
 
NCT02964377
951753
No
Not Provided
Plan to Share IPD: No
Craig McDonald, MD, University of California, Davis
Craig McDonald, MD
Cardero Therapeutics, Inc.
Not Provided
University of California, Davis
November 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP